Eli Lilly and Company: Headache trials

The registry lists 15 Headache studies with Eli Lilly and Company as lead sponsor. 0 are open to participants now and 13 have results posted.

Phase 1 1Phase 2 3Phase 3 10Phase 4 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP AntagonistCompletedNCT04294147Phase 4Results posted
• A Study of Lasmiditan (LY573144) Over Four Migraine AttacksCompletedNCT03670810Phase 3Results posted
• A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant MigraineCompletedNCT03559257Phase 3Results posted
• A Study of LY2951742 (Galcanezumab) in Japanese Participants With MigraineCompletedNCT02959190Phase 3Results posted
• A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic MigraineCompletedNCT02959177Phase 2Results posted
• A Study of LY2951742 (Galcanezumab) in Participants With Cluster HeadacheCompletedNCT02797951Phase 3Results posted
• A Safety Study of Galcanezumab in Participants With Migraine, With or Without AuraCompletedNCT02614287Phase 3Results posted
• Evaluation of Galcanezumab in the Prevention of Chronic MigraineCompletedNCT02614261Phase 3Results posted
• Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 StudyCompletedNCT02614196Phase 3Results posted
• Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 StudyCompletedNCT02614183Phase 3Results posted
• A Study of LY2951742 in Healthy VolunteersCompletedNCT01337596Phase 1Results posted
• A Study in Migraine PreventionTerminatedNCT01184508Phase 2Results posted
• Study in Participants With Acute Migraines HeadachesTerminatedNCT00804973Phase 2Results posted
• A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic MigraineActive, not recruitingNCT04616326Phase 3
• A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic MigraineActive, not recruitingNCT03432286Phase 3